76-year-old woman with Stage 3 Breast Cancer became cancer-free after… — Fact Check: Inaccurate

What was claimed

76-year-old woman with Stage 3 Breast Cancer became cancer-free after 3 months using Ivermectin (1mg/kg/day), Fenbendazole (1332mg/day), and Letrozole; earlier use of these repurposed drugs leads to higher success rates

Our verdict

Inaccurate

Multiple oncology sources emphasize that ivermectin’s anticancer data are almost entirely from lab and animal studies and that there is currently no evidence in human cancer patients that ivermectin decreases cancer growth or is effective as a chemotherapeutic agent. The only active clinical trial in metastatic triple-negative breast cancer has shown no clear benefit so far, and specialists explicitly advise against using ivermectin as a cancer treatment outside trials. Typical approved human ivermectin dosing is on the order of 150–200 µg/kg (single dose) for parasitic infections; 1 mg/kg/day is many times higher than standard and raises safety concerns.

All 3 AI systems agree9 sources citedChecked Jun 30, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

Earlier use of these repurposed drugs (ivermectin and fenbendazole) leads to higher success rates in treating breast cancer

Incorrect90%

1 of 2 AIs agree·ChatGPT: Misleading

Ivermectin and fenbendazole are effective cancer treatments that can make Stage 3 breast cancer cancer‑free in three months.

Incorrect93%

All 2 AIs agree

Ivermectin at 1 mg/kg/day is a safe or standard human dose for treating cancer.

Incorrect95%

1 AI checked

Using ivermectin and fenbendazole instead of mainstream oncology treatments is a valid and evidence-based approach

Incorrect95%

1 AI checked

Fenbendazole 1332 mg/day is an established, safe, effective human dose for cancer treatment.

Misleading85%

1 AI checked

A 76-year-old woman with Stage 3 breast cancer became cancer-free after 3 months using ivermectin (1 mg/kg/day), fenbendazole (1332 mg/day), and letrozole.

Can’t verify65%

2 of 3 AIs agree·Perplexity: Incorrect

Verified against 9 sources

Detailed Analysis

The core claims rely on a single anecdotal testimonial and are not supported by clinical evidence. Current oncology sources state that ivermectin and fenbendazole are unproven and should not be used as cancer treatments in place of standard care. The suggestion that earlier use of these drugs leads to higher success rates is speculative and contradicted by expert consensus and trial data.

Why this verdict

The core claims rely on a single anecdotal testimonial and are not supported by clinical evidence.
Current oncology sources state that ivermectin and fenbendazole are unproven and should not be used as cancer treatments in place of standard care.
The suggestion that earlier use of these drugs leads to higher success rates is speculative and contradicted by expert consensus and trial data.

Claims checked

Earlier use of these repurposed drugs (ivermectin and fenbendazole) leads to higher success rates in treating breast cancer

Incorrect90%

Oncology experts and reviews state that ivermectin and fenbendazole have only preclinical or extremely limited early-phase data in cancer, with no evidence in humans that they reduce cancer growth or improve outcomes.[4] [5] [6] [7] There are no controlled clinical trials demonstrating that earlier use of these drugs improves success rates in breast cancer; expert consensus is that their effectiveness is unknown and unproven.[4] [5] [6] [7]

This claim may mislead readers without added context.

Fenbendazole (1332mg/day) is a proven effective treatment for breast cancer in humans

Incorrect90%

Fenbendazole has shown anticancer effects in preclinical breast cancer models, including cell lines and mouse studies, but there is no evidence from human clinical trials demonstrating its efficacy as a breast cancer treatment.[3] [6] Oncology guidance notes that antiparasitic drugs like fenbendazole have not been tested in phase 1–3 trials for cancer and their effectiveness and safety in humans are unknown.[6]

This claim may mislead readers without added context.

Ivermectin (1mg/kg/day) is an effective cancer treatment that can make breast cancer patients cancer-free within months

Incorrect95%

Multiple oncology sources emphasize that ivermectin’s anticancer data are almost entirely from lab and animal studies and that there is currently no evidence in human cancer patients that ivermectin decreases cancer growth or is effective as a chemotherapeutic agent.[4] [5] [7] The only active clinical trial in metastatic triple-negative breast cancer has shown no clear benefit so far, and specialists explicitly advise against using ivermectin as a cancer treatment outside trials.[4] [5] [7]

This claim may mislead readers without added context.

What other AI think

There is no robust, peer-reviewed clinical evidence demonstrating that either ivermectin or fenbendazole is safe or effective for treating any human malignancy. The claim presents anecdotal case reports as established medical fact, misleadingly suggesting these drugs are proven cancer treatments when they remain experimental and unapproved for cancer.

Why this verdict

There is no robust, peer-reviewed clinical evidence demonstrating that either ivermectin or fenbendazole is safe or effective for treating any human malignancy.
The claim presents anecdotal case reports as established medical fact, misleadingly suggesting these drugs are proven cancer treatments when they remain experimental and unapproved for cancer.

The statement makes a specific cure claim supported only by anecdote and promotes unproven, potentially unsafe drug dosages. High-quality clinical evidence does not support ivermectin or fenbendazole as effective or approved cancer treatments, and the ivermectin dose stated is far above standard human dosing. This combination of unsupported efficacy claims and unsafe dosing constitutes dangerous misinformation.

Why this verdict

The statement makes a specific cure claim supported only by anecdote and promotes unproven, potentially unsafe drug dosages.
High-quality clinical evidence does not support ivermectin or fenbendazole as effective or approved cancer treatments, and the ivermectin dose stated is far above standard human dosing.
This combination of unsupported efficacy claims and unsafe dosing constitutes dangerous misinformation.

Claims checked

Ivermectin and fenbendazole are effective cancer treatments that can make Stage 3 breast cancer cancer‑free in three months.

Incorrect90%

There are no high‑quality randomized trials showing these antiparasitic drugs cure cancer; major cancer organizations and reviews state evidence is insufficient and these agents are not approved for cancer therapy.

This claim may mislead readers without added context.

Ivermectin at 1 mg/kg/day is a safe or standard human dose for treating cancer.

Incorrect95%

Typical approved human ivermectin dosing is on the order of 150–200 µg/kg (single dose) for parasitic infections; 1 mg/kg/day is many times higher than standard and raises safety concerns.

This claim may mislead readers without added context.

Fenbendazole 1332 mg/day is an established, safe, effective human dose for cancer treatment.

Misleading85%

Fenbendazole is a veterinary anthelmintic with no established, approved human oncology dosing; human use is experimental, unregulated, and carries safety and toxicity uncertainties.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks